John Renger - Apr 13, 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role: Chief Scientific Officer
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol: CERE
Transactions as of: Apr 13, 2022
Transactions value $: -$1,401,593
Form type: 4
Date filed: 4/15/2022, 04:19 PM
Previous filing: Mar 31, 2022
Next filing: Jul 7, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise	$158K	+45K	+2272.73%	$3.50^*	47K	Apr 13, 2022	Direct	F1
transaction	CERE	Common Stock	Sale	-$1.56M	-45K	-95.79%	$34.65	1.98K	Apr 13, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-45K	-19.08%	$0.00	191K	Apr 13, 2022	Common Stock	45K	$3.50	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.28 to $34.96 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.